O USO DE AGENTES TERAPÊUTICOS JÁ EXISTENTES PARA O ENFRENTAMENTO À COVID-19

THE USE OF EXISTING THERAPEUTIC AGENTS TO COMBAT COVID-19

Abstract

In December 2019, WHO was notified of the appearance of cases of pneumonia in the city of Wuhan (China), a week later the Chinese authorities confirmed that it was due to Coronavirus, which three months later became a pandemic. COVID-19 is caused by SARS-COV-2, which is one of seven types of human coronavirus, has quickly spread around the world. This is a narrative review of the literature on possible existing drugs and their applications in the treatment of COVID-19, since the process of creating a new drug takes many years and the problems and outcomes presented by the disease induce a character urgency in this response. Possible pharmacological and non-pharmacological therapeutic agents were presented: Azithromycin; Ivermectin, Teicoplanin, Metronidazole, Remdesivir, Favipiravir, Lopinavir, Ritonavir, Low molecular weight heparins, Tocilizumab, Chloroquine, Hydroxychloroquine, Zinc, N-acetylcysteine, anti-CD147 antibodies, melatonin, passive immunotherapy and monoclonal antibodies. Amount of expressive data in humans and the possibilities of toxicity and drug interactions suggest that prescribers should be careful and wait for more conclusive data and recommendations from competent bodies for the use of most available agents to combat COVID-19.